Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Wang, Guan ^a   He, Jing ^a   Zhao, Jianyun ^a   Yun, Wenting ^a   Xie, Chengzhi ^a,c   Taub, Jeffrey W ^b,c   Azmi, Asfar ^c   Mohammad, Ramzi M ^c   Dong, Yan ^a,d   Kong, Wei ^a   Guo, Yingjie ^a   Ge, Yubin ^a,c  

^a JILIN UNIVERSITY   (China)

^b CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 [3 (3 FLUOROPHENYL) 3 OXO 1 PROPENYL] 1 METHYL 1H PYRROL 2 YL]ACRYLOHYDROXAMIC ACID; ALPHA TUBULIN; DOUBLE STRANDED DNA; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; HISTONE H2AX; HISTONE H4; MOCETINOSTAT; PROTEIN P21; TUBASTATIN A; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL DEATH; COLONY FORMATION; COMPUTER PROGRAM; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG TARGETING; ENZYME ASSAY; EPITHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER; PANCREAS DUCT; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN INTERACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL DEATH; CELL DIVISION; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA BREAKS, DOUBLE-STRANDED; EPITHELIAL CELLS; G2 PHASE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; TUBULIN;

EID: 84871273907     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052095     Document Type: Article

References (50)

1. Siegel R, Ward E, Brawley O, Jemal A, (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
2. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M, et al. (2006) Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther 5: 1387-1395.
3. Strimpakos A, Saif MW, Syrigos KN, (2008) Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev 27: 495-522.
4. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413.
5. Kullmann F, Hollerbach S, Dollinger MM, Harder J, Fuchs M, et al. (2009) Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. Br J Cancer 100: 1032-1036.
6. Li J, Saif MW, (2009) Advancements in the management of pancreatic cancer. JOP 10: 109-117.
7. Carew JS, Giles FJ, Nawrocki ST, (2008) Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 269: 7-17.
8. Witt O, Deubzer HE, Milde T, Oehme I, (2009) HDAC family: What are the cancer relevant targets? Cancer Lett 277: 8-21.
9. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB, (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370: 737-749.
10. Gregoretti IV, Lee YM, Goodson HV, (2004) Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338: 17-31.
11. Verdin E, Dequiedt F, Kasler HG, (2003) Class II histone deacetylases: versatile regulators. Trends Genet 19: 286-293.
12. Guardiola AR, Yao TP, (2002) Molecular cloning and characterization of a novel histone deacetylase HDAC10. J Biol Chem 277: 3350-3356.
13. Blander G, Guarente L, (2004) The Sir2 family of protein deacetylases. Annu Rev Biochem 73: 417-435.
14. Ledent V, Vervoort M, (2006) Comparative genomics of the class 4 histone deacetylase family indicates a complex evolutionary history. BMC Biol 4: 24.
15. Feinberg AP, Ohlsson R, Henikoff S, (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7: 21-33.
16. Sung V, Richard N, Brady H, Maier A, Kelter G, et al. (2011) Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells. Cancer Sci 102: 1201-1207.
17. Sasaki H, Moriyama S, Nakashima Y, Kobayashi Y, Kiriyama M, et al. (2004) Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 46: 171-178.
18. Miyake K, Yoshizumi T, Imura S, Sugimoto K, Batmunkh E, et al. (2008) Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 36: e1-9.
19. Marks PA, (2010) The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 19: 1049-1066.
20. Bolden JE, Peart MJ, Johnstone RW, (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784.
21. Chun SG, Zhou W, Yee NS, (2009) Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer. Cancer Biol Ther 8: 1328-1339.
22. Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, et al. (2007) Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 121: 656-665.
23. Arnold NB, Arkus N, Gunn J, Korc M, (2007) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 13: 18-26.
24. Kauh J, Fan S, Xia M, Yue P, Yang L, et al. (2010) c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS One 5: e10376.
25. Glaser KB, Li J, Staver MJ, Wei RQ, Albert DH, et al. (2003) Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 310: 529-536.
26. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, et al. (2002) Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 21: 2672-2681.
27. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, et al. (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280: 26729-26734.
28. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, et al. (2010) Chemical phylogenetics of histone deacetylases. Nat Chem Biol 6: 238-243.
29. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, et al. (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 409: 581-589.
30. Duong V, Bret C, Altucci L, Mai A, Duraffourd C, et al. (2008) Specific activity of class II histone deacetylases in human breast cancer cells. Mol Cancer Res 6: 1908-1919.
31. Mai A, Massa S, Pezzi R, Rotili D, Loidl P, et al. (2003) Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A. J Med Chem 46: 4826-4829.
32. Mai A, Massa S, Pezzi R, Simeoni S, Rotili D, et al. (2005) Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J Med Chem 48: 3344-3353.
33. Butler KV, Kalin J, Brochier C, Vistoli G, Langley B, et al. (2010) Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc. 132: 10842-10846.
34. Deer EL, Gonzalez-Hernandez J, Coursen JD, Shea JE, Ngatia J, et al. (2010) Phenotype and genotype of pancreatic cancer cell lines. Pancreas 39: 425-435.
35. Xie C, Edwards H, Xu X, Zhou H, Buck SA, et al. (2010) Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res 16: 5499-5510.
36. Xu X, Xie C, Edwards H, Zhou H, Buck SA, et al. (2011) Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells. PLoS One 6: e17138.
37. Chou TC, (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681.
38. Tallarida RJ, (2001) Drug synergism: its detection and applications. J Pharmacol Exp Ther 298: 865-872.
39. Edwards H, Xie C, LaFiura KM, Dombkowski AA, Buck SA, et al. (2009) RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood 114: 2744-2752.
40. Ge Y, Stout ML, Tatman DA, Jensen TL, Buck S, et al. (2005) GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. J Natl Cancer Inst 97: 226-231.
41. Xie C, Edwards H, Lograsso SB, Buck SA, Matherly LH, et al. (2012) Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells. Pediatr Blood Cancer 59: 1245-1251.
42. Conti C, Leo E, Eichler GS, Sordet O, Martin MM, et al. (2010) Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res 70: 4470-4480.
43. Gaymes TJ, Padua RA, Pla M, Orr S, Omidvar N, et al. (2006) Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis? Mol Cancer Res 4: 563-573.
44. Dai Y, Grant S, (2010) New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 16: 376-383.
45. Minucci S, Pelicci PG, (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51.
46. Redon CE, Nakamura AJ, Zhang YW, Ji JJ, Bonner WM, et al. (2010) Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res 16: 4532-4542.
47. Prince HM, Bishton MJ, Harrison SJ, (2009) Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15: 3958-3969.
48. Huang BH, Laban M, Leung CH, Lee L, Lee CK, et al. (2005) Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 12: 395-404.
49. Karagiannis TC, El-Osta A, (2007) Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? Leukemia 21: 61-65.
50. Namdar M, Perez G, Ngo L, Marks PA, (2010) Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci U S A 107: 20003-20008.